AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

The phosphatidylinositol-3-kinase (PI3 kinase)-AKT pathway is frequently activated in cancer. Recent reports have identified a transforming mutation of AKT1 in breast, colorectal, ovarian and lung cancers. We report here the occurrence of this mutation in bladder tumours. The AKT1 G49A (E17K) mutation was found in 2/44 (4.8%) bladder cancer cell lines and 5/184 (2.7%) bladder tumours. Cell lines expressing mutant AKT1 show constitutive AKT1 activation under conditions of growth factor withdrawal. We also detected a novel AKT1 mutation G145A (E49K). This mutation also enhances AKT activation and shows transforming activity in NIH3T3 cells, though activity is weaker than that of E17K. Enhanced activation of AKT1 when E17K and E49K mutations are in tandem suggests that they can co-operate.

[1]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[2]  A. Marchetti,et al.  AKT1E17K in human solid tumours , 2008, Oncogene.

[3]  N. C. Price,et al.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. , 2003, The Biochemical journal.

[4]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[5]  S. H. Lee,et al.  Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias , 2008, British Journal of Cancer.

[6]  W. Gregory,et al.  Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer , 2009, Clinical Cancer Research.

[7]  B. Hemmings,et al.  PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. , 2008, Molecular cell.

[8]  François Radvanyi,et al.  Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder , 1997, Oncogene.

[9]  J. Falke,et al.  Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. , 2008, Biochemistry.

[10]  M. Hung,et al.  Signaling intricacies take center stage in cancer cells. , 2005, Cancer research.

[11]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[12]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[13]  M. Knowles,et al.  Somatic mutation of PTEN in bladder carcinoma , 1999, British Journal of Cancer.

[14]  Biao Dong,et al.  Ca2+/Calmodulin Directly Interacts with the Pleckstrin Homology Domain of AKT1* , 2007, Journal of Biological Chemistry.

[15]  N. Malats,et al.  PIK3CA MUTATIONS ARE AN EARLY GENETIC ALTERATION ASSOCIATED WITH FGFR3 MUTATIONS IN SUPERFICIAL PAPILLARY BLADDER TUMORS , 2006 .

[16]  T. Tsuruo,et al.  Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. , 2007, Cancer research.

[17]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[18]  B. Vojnovic,et al.  Intramolecular and Intermolecular Interactions of Protein Kinase B Define Its Activation In Vivo , 2007, PLoS biology.

[19]  G. Viglietto,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. , 2008, Cell cycle.

[20]  J. Laine,et al.  The protooncogene TCL1 is an Akt kinase coactivator. , 2000, Molecular cell.

[21]  A. Moinzadeh,et al.  Molecular analysis of PTEN and MXI1 in primary bladder carcinoma , 2000, International journal of cancer.

[22]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[23]  M. Knowles,et al.  Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. , 2003, Cancer research.

[24]  Maria Deak,et al.  High-Resolution Structure of the Pleckstrin Homology Domain of Protein Kinase B/Akt Bound to Phosphatidylinositol (3,4,5)-Trisphosphate , 2002, Current Biology.

[25]  M. Knowles,et al.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms , 2008, Human molecular genetics.

[26]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[27]  G. Mills,et al.  A new mutational AKTivation in the PI3K pathway. , 2007, Cancer cell.